The significant differences in DFS according to BCL-2 expression classes were more apparent in the subgroup of younger patients (P = 0.0140), with T1 (P = 0.032), N1 (P = 0.033) tumours, carcinomas characterized by negativity of CK5/6 (P = 0.043), HER2 (P = 0.019) and P53 (P = 0.037), low MVD (P = 0.013) and only for patients with cancers having TN immunophenotype. This evidence concerns the gene BCL2 and cancer.